Then, multiple clinical trials verified the efficacy of disitamab vedotin in Her-2–positive patients in various tumors, including urothelial cancer, breast cancer, and biliary tract cancer, and so forth (12)., thus indicating a potential treatment strategy for those tumors with high Her-2 expression. This evidence concerns the gene ERBB2 and breast carcinoma.